Pattern Bioscience

Rapid bacterial infection diagnostics and analysis

Austin, Texas, United States

About Pattern Bioscience

Pattern Bioscience specializes in the rapid identification of bacterial infections and their antibiotic resistance profiles. The company uses advanced digital technology that combines single-cell analysis with AI pattern recognition to provide ID/AST results in just four hours, a significant reduction from traditional methods that can take days. Its primary customers are hospitals and healthcare providers, including lab directors and infection prevention specialists. Pattern Bioscience differentiates itself by offering faster and more accurate diagnostics, which helps reduce unnecessary antibiotic prescriptions and combat antibiotic resistance. The company's goal is to improve patient outcomes and address the global health threat posed by antibiotic misuse.

Austin, TexasHeadquarters
2016Year Founded
$47.2MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, HealthcareIndustries
51-200Employees

Risks

Emerging competition from companies like Accelerate Diagnostics threatens market share.
Regulatory delays could slow down market entry for new diagnostic technologies.
AI-driven analysis tools may face risks of biases and errors affecting accuracy.

Differentiation

Pattern Bioscience uses patented phenotypic single-cell technology for pathogen identification.
Their Digital CultureTM technology offers comprehensive resistance mechanism analysis.
AI pattern recognition enables rapid ID/AST results in just four hours.

Upsides

Raised $28.7 million in Series C funding to accelerate platform development.
Growing demand for rapid diagnostics due to COVID-19 pandemic boosts market potential.
U.S. government funding for antibiotic resistance aligns with Pattern's mission.

Funding

Total raised$47.24 M
Latest valuation$143.50 M
StageSERIES_C
$9
$45.00 M
GRANT
12/31/2018
N/A
SERIES A
4/30/2018
$4
$18.75 M